Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xerigo
- Development stage
- Unknown
- Lead developer
- Brinton Pharmaceuticals
- Administration
- Topical
01
Overview
Xerigo is an intense moisturizing cream developed by Brinton Pharmaceuticals for the management of dry, rough, and scaly skin conditions, particularly on cracked feet, elbows, and knees. The triple-action formulation functions as an emollient, humectant, and exfoliator. It is enriched with key ingredients such as glycolic acid, urea, vitamin E (tocopheryl acetate), and lavender oil, which work synergistically to gently exfoliate dead skin cells, deeply hydrate the skin, prevent moisture loss, and soothe irritation.
- Brand names
- Xerigo
- Other names
- Xerigo CreamXerigo Intense Skin Moisturizing Cream
Beyond the preview
Go deeper on Xerigo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xerigo.